22 November 2017
News and Views
Links and Services
Bevacizumab reduces high cardiac output and epistaxis in severe hepatic forms of hereditary hemorrhagic telangiectasia, reports this week's Journal of the American Medical Association.
The only treatment available to restore normal cardiac output in patients with hereditary hemorrh
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors